# US 2021/0277449 A1 · Non-invasive diagnosis of graft rejection in organ transplant patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277449 A1
- Document ID: US20210277449A1
- Status: Published application
- Kind: A1
- Application number: 17/323,917
- Filed: 2021-05-18
- Published: 2021-09-09
- Earliest claimed: 2009-11-06
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Stephen R. Quake; Thomas M. Snyder; Hannah Valantine
- Web page: https://patentgrep.com/patent/US20210277449A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6869: Methods for sequencing
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 1/6858: Allele-specific amplification
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.

## Claims

### Claim 1

A method of preparing a blood sample from a solid organ transplant recipient for a next-generation sequencing reaction, the method comprising:
a. obtaining a blood sample from the solid organ transplant recipient;
b. isolating a plasma fraction from the blood sample from the solid organ transplant recipient, wherein the plasma fraction comprises cell-free nucleic acids from a solid organ transplant;
c. extracting nucleic acids from the plasma fraction to obtain extracted nucleic acids from the plasma fraction from the solid organ transplant recipient;
d. preparing the extracted nucleic acids from the plasma sample from the solid organ transplant recipient for a next generation sequencing assay to obtain prepared extracted cell-free nucleic acids;
e. sequencing the prepared extracted cell-free nucleic acids using a next-generation sequencing assay to obtain nucleic acid sequence data of the extracted cell-free nucleic acids.

### Claim 2 (depends on 1)

The method of claim 1, further comprising identifying one or more polymorphisms within the sequenced extracted cell-free nucleic acids.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more polymorphisms comprise single nucleotide polymorphisms.

### Claim 4 (depends on 1)

The method of claim 1, further comprising selectively amplifying one or more polymorphisms from the extracted nucleic acids from the plasma fraction from the solid organ transplant recipient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the one or more polymorphisms comprise single nucleotide polymorphisms.

### Claim 6 (depends on 1)

The method of claim 1, wherein the blood sample comprises an anticoagulant.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell-free nucleic acids comprise DNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the prepared extracted cell-free nucleic acids comprise DNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the extracted cell-free nucleic acids comprise less than 200 nanograms of DNA.

### Claim 10 (depends on 1)

The method of claim 1, wherein the extracted cell-free nucleic acids comprise less than 100 nanograms of DNA.

### Claim 11 (depends on 1)

The method of claim 1, wherein a volume of the blood sample is from 1 to 50 milliliters.

### Claim 12 (depends on 1)

The method of claim 1, wherein a volume of the blood sample is from 4 to 20 milliliters.

### Claim 13 (depends on 1)

The method of claim 1, further comprising genotyping the solid organ transplant recipient to obtain a recipient single nucleotide polymorphism profile comprising a plurality of single nucleotide polymorphisms of the solid organ transplant recipient.

### Claim 14 (depends on 1)

The method of claim 1, further comprising genotyping a donor of the solid organ transplant to obtain a donor single nucleotide polymorphism profile comprising a plurality of single nucleotide polymorphisms of the solid organ transplant donor.

### Claim 15 (depends on 1)

The method of claim 1, wherein the solid organ transplant comprises a kidney transplant, a heart transplant, liver transplant, pancreas transplant, lung transplant, intestine transplant skin transplant, and combinations thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the solid organ transplant comprises a lung transplant.

### Claim 17 (depends on 1)

The method of claim 1, wherein the solid organ transplant comprises a kidney transplant.

### Claim 18 (depends on 1)

The method of claim 1, wherein the solid organ transplant comprises a heart transplant.

### Claim 19 (depends on 1)

The method of claim 1, wherein the next-generation sequencing assay is a sequencing-by-synthesis assay.

### Claim 20 (depends on 1)

The method of claim 1, wherein the nucleic acid sequence data of the extracted cell-free nucleic acids comprises sequence information of one or more homozygous single nucleotide polymorphisms, heterozygous single nucleotide polymorphisms, or both homozygous single nucleotide polymorphisms and heterozygous single nucleotide polymorphisms, of the recipient or a donor.
